As a cutting-edge therapeutic approach, antisense oligonucleotide drugs precisely target the mRNA or pre-mRNA of disease-causing genes.

Jubilant Therapeutics Inc. has reported the initial dosing of patients in worldwide clinical trials for JBI-802, a CoREST inhibitor, and JBI-778, a PRMT5 inhibitor.

Otsuka Pharmaceutical announced positive top-line interim data from the phase III clinical trial of sibeprenlimab for treating adults with IgA nephropathy.

Maze Therapeutics announces encouraging initial human data from a Phase 1 trial involving healthy participants.

Hope Medicine (HopeMed) announced positive interim results from a Phase 2 study of HMI-115 in women with moderate to severe endometriosis-associated pain.

Kymera Therapeutics has begun administering doses to the initial participant in its Phase 1 clinical trial of KT-621.

Tonix Pharmaceuticals announced that it has submitted a New Drug Application (NDA) to the U.S. FDA for TNX-102 SL (Cyclobenzaprine hydrochloride).

Intellia Announces Encouraging Outcomes from Phase 2 Trial of NTLA-2002, a CRISPR Gene Editing Therapy for Hereditary Angioedema (HAE).

Longboard Pharmaceuticals has recently announced the initiation of the global Phase 3 DEEp SEA study.

Skyhawk Therapeutics showcases impressive preclinical findings for SKY-1214 at the EORTC-NCI-AACR Molecular Targets and Cancer Treatments Symposium.

Novo Nordisk announced on its official website the primary results of a Phase 2a clinical trial for its investigational drug monlunabant (previously known as INV-202).

Accent Therapeutics has received FDA approval for its IND application for ATX-559, the first oral inhibitor targeting DHX9.